Previous 10 | Next 10 |
Gainers: AN2 Therapeutics (ANTX) +7%. Design Therapeutics (DSGN) +6%. Edgio (EGIO) +5%. Humacyte (HUMA) +5%. Rhythm Pharmaceuticals (RYTM) +5%. Losers: Swvl Holdings (SWVL) -10%. Amedisys (AMED) -8%. Lilium (LILM) -5%. Centessa Pharmaceuticals (CNTA) -5%. KLX Energy Services Holding...
AN2 Therapeutics press release (NASDAQ:ANTX): Q1 GAAP EPS of -$2.98 misses by $2.06. Cash, equivalents and short-term investments totaled $118.4M on March 31, 2022. The company expects that current cash, cash equivalents and investments, including net proceeds from the underwriters' over-allo...
On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Beg...
AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release featu...
Oppenheimer has initiated AN2 Therapeutics (NASDAQ:ANTX) with an outperform rating arguing that its anti-infective epetraborole could become part of the standard of care for refractory non-tuberculous mycobacterial (NTM) infections. The firm has a $22 price target (~49% upside based on Monday...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
The IPO market stayed relatively quiet, with only one IPO and one SPAC pricing this past week. Pipeline activity maintained its slow pace, with only two small IPOs and one SPAC submitting initial filings. No IPOs are currently scheduled to price in the week ahead, though a few SPACs m...
AN2 Therapeutics (ANTX) shares jumped 8% following the biotech company's initial public offering on Friday. The company, which develops treatments for rare infectious diseases, saw its stock open at $16.85 after pricing at $15 per share, reaching a high of $17.80 before dipping to $15.49. Sha...
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of its upsized initial public offe...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...